OpenAI has introduced a new ai model called GPT-Rosalind, which is intended for life sciences research. The model is reportedly designed to accelerate drug discovery and research workflows, although some outlets suggest it may have a broader focus, including biodefense. The extent of its capabilities and access to the model are not entirely clear, with some reports indicating it may have limited access.